ATE319817T1 - Gegen inaktivierung resistenter faktor viii - Google Patents

Gegen inaktivierung resistenter faktor viii

Info

Publication number
ATE319817T1
ATE319817T1 AT97927596T AT97927596T ATE319817T1 AT E319817 T1 ATE319817 T1 AT E319817T1 AT 97927596 T AT97927596 T AT 97927596T AT 97927596 T AT97927596 T AT 97927596T AT E319817 T1 ATE319817 T1 AT E319817T1
Authority
AT
Austria
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Application number
AT97927596T
Other languages
German (de)
English (en)
Inventor
Randal J Kaufman
Steven W Pipe
Kagehiro Amano
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE319817T1 publication Critical patent/ATE319817T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97927596T 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii ATE319817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ATE319817T1 true ATE319817T1 (de) 2006-03-15

Family

ID=26688196

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Country Status (10)

Country Link
US (2) US6838437B2 (enExample)
EP (3) EP1754718B1 (enExample)
JP (2) JP3987114B2 (enExample)
AT (2) ATE319817T1 (enExample)
AU (1) AU3202797A (enExample)
CA (1) CA2252896C (enExample)
DE (2) DE69740154D1 (enExample)
DK (1) DK1754718T3 (enExample)
PT (1) PT1754718E (enExample)
WO (1) WO1997040145A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507664A (ja) * 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
WO1999041385A1 (en) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
WO2006067230A1 (en) * 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
EP1874815A1 (en) * 2005-04-14 2008-01-09 CSL Behring GmbH Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
AU2007269233B2 (en) * 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CN103298483B (zh) * 2010-11-05 2017-04-12 百深有限责任公司 具有增加的比活性的抗血友病因子viii的新型变体
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
ES2600081T3 (es) 2011-10-18 2017-02-07 Csl Behring Gmbh Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
IN2012CH03778A (enExample) * 2012-09-12 2015-04-24 Ct For Bioseparation Technology Vit
WO2014085527A1 (en) 2012-11-29 2014-06-05 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein c and uses thereof
CA2892750A1 (en) * 2012-11-29 2014-06-05 Bayer Healthcare Llc Monoclonal antibodies agaisnt activated protein c (apc)
CA2906602A1 (en) * 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
CN106659771B (zh) 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
AU2016231328B2 (en) * 2015-03-06 2018-07-05 CSL Behring Lengnau AG Compounds for improving the half-life of von Willebrand factor
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CN107787328B (zh) 2015-05-22 2021-08-06 康诺贝林伦瑙有限公司 用于治疗血友病的截短的血管性血友病因子多肽
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
AU2019366942B2 (en) * 2018-10-23 2025-10-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
FI873796A7 (fi) 1986-01-03 1987-09-01 Genetics Inst Parannettu menetelmä VIII:c-tekijän tyyppisen proteiinin tuottamiseks i.
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
HUT70457A (en) 1989-11-17 1995-10-30 Chiron Corp Protein complexes having factor viii:c activity and production thereof
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6456096A (en) 1995-07-11 1997-02-10 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii

Also Published As

Publication number Publication date
EP0910628B1 (en) 2006-03-08
US20060014683A1 (en) 2006-01-19
EP0910628A1 (en) 1999-04-28
AU3202797A (en) 1997-11-12
ATE502958T1 (de) 2011-04-15
CA2252896A1 (en) 1997-10-30
EP0910628A4 (en) 2001-05-02
EP1754718A2 (en) 2007-02-21
CA2252896C (en) 2009-03-10
JP2007228973A (ja) 2007-09-13
JP4250661B2 (ja) 2009-04-08
DE69735421D1 (de) 2006-05-04
US6838437B2 (en) 2005-01-04
EP1754718B1 (en) 2011-03-23
JP2000511407A (ja) 2000-09-05
EP2202242A1 (en) 2010-06-30
JP3987114B2 (ja) 2007-10-03
DE69735421T2 (de) 2006-10-19
US20020132306A1 (en) 2002-09-19
US7459534B2 (en) 2008-12-02
EP1754718A3 (en) 2007-05-16
PT1754718E (pt) 2011-07-13
WO1997040145A1 (en) 1997-10-30
DE69740154D1 (de) 2011-05-05
DK1754718T3 (da) 2011-07-18

Similar Documents

Publication Publication Date Title
ATE319817T1 (de) Gegen inaktivierung resistenter faktor viii
DK0672138T3 (da) Kimære prokoagulante proteiner
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
EP0731636A4 (en) APOPTOSIS-MODULATING PROTEINS, DNA-ENCODING, AND METHOD FOR THEIR USE
ATE423194T1 (de) Von-willebrand-faktor (vwf) spaltendes protease- polypeptid, für das polypeptid codierende nukleinsäure und verwendung des polypeptids
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
AU3793493A (en) Therapeutic domains of von willebrand factor
ATE148992T1 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
MX9708426A (es) Polipeptido hk2 de variante estable.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
SE9602822D0 (sv) New receptor
ATE190630T1 (de) Angiotensin-ii typ-1 rezeptor und dessen herstellung
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
FI921356A0 (fi) Somatostatinreceptor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties